Abstract
The term “disease modifying drugs” (DMD) is taken from rheumatologists who coined it after the use of immunosuppressive drugs and, more recently, the association of “biological drugs” that changed the degenerative course of rheumatic disease.
In the treatment of multiple sclerosis (MS), the advent of interferon (IFN)-β, which caused a reduction in the number of relapses and possibly improvement in disability outcomes, was the first strategy to prevent inflammatory damage in the central nervous system (CNS). Soon after, glatiramer acetate showed similar results. It would be more than a decade before natalizumab was licensed, showing a much better efficiency in relapse reduction than was seen after first-line therapies failed. The pipeline is now much larger with several drugs on the horizon. Overall, the anti-inflammatory strategy has been mostly successful but drugs that have protection and repair mechanisms are still missing.
Keywords: Multiple sclerosis, treatments, mechanisms of action.
CNS & Neurological Disorders - Drug Targets
Title:Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon
Volume: 11 Issue: 5
Author(s): Monica Marta and Gavin Giovannoni
Affiliation:
Keywords: Multiple sclerosis, treatments, mechanisms of action.
Abstract: The term “disease modifying drugs” (DMD) is taken from rheumatologists who coined it after the use of immunosuppressive drugs and, more recently, the association of “biological drugs” that changed the degenerative course of rheumatic disease.
In the treatment of multiple sclerosis (MS), the advent of interferon (IFN)-β, which caused a reduction in the number of relapses and possibly improvement in disability outcomes, was the first strategy to prevent inflammatory damage in the central nervous system (CNS). Soon after, glatiramer acetate showed similar results. It would be more than a decade before natalizumab was licensed, showing a much better efficiency in relapse reduction than was seen after first-line therapies failed. The pipeline is now much larger with several drugs on the horizon. Overall, the anti-inflammatory strategy has been mostly successful but drugs that have protection and repair mechanisms are still missing.
Export Options
About this article
Cite this article as:
Marta Monica and Giovannoni Gavin, Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon, CNS & Neurological Disorders - Drug Targets 2012; 11 (5) . https://dx.doi.org/10.2174/187152712801661301
DOI https://dx.doi.org/10.2174/187152712801661301 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Plant Phenolic Compounds as Potential Lead Compounds in Functional Foods for Antiviral Drug Discovery
Current Organic Chemistry Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges
Current Neuropharmacology Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry Protein Conformational Diseases: From Mechanisms to Drug Designs
Current Drug Discovery Technologies The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Pentapeptides as Minimal Functional Units in Cell Biology and Immunology
Current Protein & Peptide Science Meet Our Editorial Board Member
Clinical Cancer Drugs Discovery, SAR and Medicinal Chemistry of Herpesvirus Helicase Primase Inhibitors
Current Medicinal Chemistry - Anti-Infective Agents Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Immunomodulation in Trichinellosis: Does Trichinella Really Escape the Host Immune System?
Endocrine, Metabolic & Immune Disorders - Drug Targets Natural Triterpenoids and their Derivatives with Pharmacological Activity Against Neurodegenerative Disorders
Mini-Reviews in Organic Chemistry Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Current Pharmaceutical Design Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot Topic: Protein Peptide Informatics and Drug Designing - Some Computational Techniques for Structural Genomics Based Approaches (Part II) (Guest Editor: Rajani R. Joshi)]
Protein & Peptide Letters Translating Nucleic Acid Amplification Assays to the Microscale: Lab on a Chip for Point-of-Care Molecular Diagnostics
Current Analytical Chemistry Plasmid DNA Manufacturing Technology
Recent Patents on Biotechnology From Alpha to Omega with Aβ: Targeting the Multiple Molecular Appearances of the Pathogenic Peptide in Alzheimers Disease
Current Medicinal Chemistry Abnormal Functional and Structural Asymmetry as Biomarker for Schizophrenia
Current Topics in Medicinal Chemistry